Related Experiment Video
Updated: Aug 29, 2025
15:03
Synthesis of Functionalized Magnetic Nanoparticles, Their Conjugation with the Siderophore Feroxamine and its Evaluation for Bacteria Detection
Published on: June 16, 2020
9.4K
Silica-Coated Magnetic Nanoparticles for Vancomycin Conjugation
Moustafa M Abdelaziz1, Amr Hefnawy2, Asem Anter3
1Department of Bioengineering, The University of Kansas, Lawrence, Kansas 66045, United States.
ACS Omega
|September 5, 2022
Summary
Researchers developed vancomycin-conjugated magnetic nanoparticles to combat bacterial multidrug resistance (MDR). This targeted approach enhances antibacterial efficiency and safety, offering a promising platform for drug delivery.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Infectious Diseases
Background:
- Bacterial multidrug resistance (MDR) is a critical global health threat, with limited new antibacterial agents.
- Vancomycin is effective but has severe side effects, limiting its clinical application.
- Targeted drug delivery systems can improve therapeutic efficacy and reduce toxicity.
Purpose of the Study:
- To develop vancomycin-conjugated magnetic nanoparticles for targeted antibacterial activity.
- To create a novel drug delivery platform to overcome vancomycin's limitations.
- To assess the physicochemical properties, biocompatibility, and antibacterial efficacy of the new formulation.
Main Methods:
- Synthesized silica-coated magnetic nanoparticles.
- Conjugated vancomycin to the nanoparticles via an amide linker.
- Characterized nanoparticle morphology, size, and vancomycin conjugation efficiency.
- Assessed magnetic properties, in vitro cell biocompatibility, and antibacterial activity.
Main Results:
- Developed spherical nanoparticles (16.3 ± 2.6 nm) with efficient vancomycin conjugation (25.1%).
- Formulation retained magnetic properties and demonstrated improved in vitro biocompatibility (IC50 183.43 μg/mL vs. 54.11 μg/mL for free vancomycin).
- Antibacterial activity was comparable to free vancomycin, with a Minimum Inhibitory Concentration (MIC) of 25 μg/mL.
Conclusions:
- Vancomycin-conjugated magnetic nanoparticles offer a viable platform for targeted drug delivery.
- This approach enhances vancomycin's safety profile while maintaining antibacterial efficacy.
- The developed nanoparticles show potential for treating drug-resistant bacterial infections.
